Late Breaking Abstract - Clinical remission with dupilumab in children with uncontrolled, moderate-to-severe, type 2 asthma - Vienna 2024

ALERT 2: Fighting the burden of asthma and respiratory symptoms

Chair(s): Kristin Walter, Richard Costello, Anne Holland, Arnaud Bourdin

Session type: Clinical trials session

Late Breaking Abstract - Clinical remission with dupilumab in children with uncontrolled, moderate-to-severe, type 2 asthma

Leonard Bacharier

EVENTS HOME

Previous presentation

Next presentation

Session content

RCT Abstract - Treating eosinophilic exacerbations of asthma and COPD with benralizumab: a double-blind, double-dummy, active-placebo randomised controlled trial (ABRA)

Mona Bafadhel

Replay

Abstract

Slides

RCT Abstract - At-Risk Registers Integrated into primary care to Stop Asthma crises in the UK

Andrew Wilson

Replay

Abstract

Slides

Late Breaking Abstract - Depemokimab efficacy/safety in patients with asthma on medium/high-dose ICS: The Phase IIIA randomised SWIFT-1/2 studies

David Jackson

Replay

Abstract

Slides

Late Breaking Abstract - Clinical remission with dupilumab in children with uncontrolled, moderate-to-severe, type 2 asthma

Leonard Bacharier

Replay

Abstract

Slides

Wrap-up by discussant and discussion

Arnaud Bourdin

Replay

Slides

RCT Abstract - Mirtazapine to alleviate severe breathlessness in patients with COPD or ILD: an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial (BETTER-B).

Irene Higginson

Replay

Abstract

Slides

Late Breaking Abstract - Symptom-based rehabilitation (REHAB) vs. usual care in people with post COVID-19 condition the Reload trial: a randomized controlled trial (RCT)

Tessa Schneeberger

Replay

Abstract

Slides

Wrap-up by discussant and discussion

Anne Holland

Replay

Slides

Closing remarks

Replay

Session aims

The ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials) showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, discussants, session chairs and the audience will actively discuss the showcased trials.

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}